Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 3
Submit an article Journal homepage
63
Views
40
CrossRef citations to date
0
Altmetric
Review

The potential of nitric oxide therapeutics in stroke

MR Willmot Division of Stroke Medicine, Clinical Sciences Building, University of Nottingham, Nottingham NG5 1PB, UK
&
PMW Bath Division of Stroke Medicine, Clinical Sciences Building, University of Nottingham, Nottingham NG5 1PB, UK
Pages 455-470 | Published online: 02 Mar 2005

Bibliography

  • ISARD P, FORBES J: The cost of stroke to the National Health Service in Scotland. Cerebrovasc. Dis. (1992) 2:47–50.
  • INTERNATIONAL STROKE TRIAL COLLABORATIVE GROUP: The International Stroke Trial (1ST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet (1997) 349:1569–1581.
  • DIRNAGL U, IADECOLA C, MOSKOWITZ MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. (1999) 22(9):391–397.
  • ••An excellent review which draws togetherthe varied and complex pathophysiological events that occur after stroke.
  • FURCHGOTT RF, ZAWADZKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288(5789):373–376.
  • PALMER RM, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327(6122):524–526.
  • MARIN J, RODRIGUEZ-MARTINEZ MA: Role of vascular nitric oxide in physiological and pathological conditions. Pharmacol Ther. (1997) 75(2):111–134.
  • ••A good review article on the functions ofNO in health and disease.
  • SCHMIDT HH, LOHMANN SM, WALTER U: The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim. Biophys. Acta (1993) 1178(2):153–175.
  • DENNINGER JW, MARLETTA MA: Guanylate cyclase and the NO/cGMP signaling pathway. Bloch/m. Biophys. Acta (1999) 1411(2-3):334–350.
  • BECKMAN JS, KOPPENOL WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. I Physiol (1996) 271(5, Pt 1):C1424–1437.
  • VALLANCE P, COLLIER J, MONCADA S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 2(8670):997–1000.
  • FLEMING I, BUSSE R: Control and consequences of endothelial nitric oxide formation. Adv. Pharmacol. (1995) 34:187–206.
  • SHI Y, BAKER JE, ZHANG C, TWEDDELL JS, SU J, PRITCHARD KA Jr: Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation. Circ. Res. (2002) 91(4):300–306.
  • REES DD, PALMER RM, MONCADA S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA (1989) 86(9):3375–3378.
  • WELCH G, LOSCALZO J: Nitric oxide and the cardiovascular system. J. Cardiovasc. Surg. (1994) 9(3):361–371.
  • MCALLISTER RM, HIRAI T, MUSCH TI: Contribution of endothelium-derived nitric oxide (EDNO) to the skeletal muscle blood flow response to exercise. Med. Sci. Sports Exerc. (1995) 27(8):1145–1151.
  • BURNETT AL, TILLMAN SL, CHANG TS et al.: Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. UroL (1993) 150(1):73–76.
  • BATH PMW, HASSALL DG, GLADWIN A-M, PALMER RMJ, MARTIN JF: Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler. Thromb. (1991) 11:254–260.
  • BATH PMW: The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur. 1 Clin. Pharmacol (1993) 45:53–58.
  • GARG UC, HASSID A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. (1989) 83(5):1774–1777.
  • CARDONA-SANCLEMENTE LE, BORN GV: Effect of inhibition of nitric oxide synthesis on the uptake of LDL and fibrinogen by arterial walls and other organs of the rat. Br. J. Pharmacol (1995) 114(7):1490–1494.
  • KIM YM, TALANIAN RV, BILLIAR TR: Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J. Biol. Chem. (1997) 272(49):31138–31148.
  • MURPHY S: Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Clio (2000) 29(1):1–13.
  • •A good summary of the beneficial and detrimental roles of NO in the nervous system.
  • LAROUX FS, PAVLICK KP, HINES IN et al.: Role of nitric oxide in inflammation. Acta Physiol Scand. (2001) 173(1):113–118.
  • •A review of the current knowledge on regulatory mechanisms of NO in Inflammation.
  • BRUNE B, VON KNETHEN A, SANDAU KB: Nitric oxide and its role in apoptosis. Eur. 1 Pharmacol (1998) 351(3):261–272.
  • •A good discussion on the role of NO in apotosis.
  • SIMS NR, ANDERSON MF: Mitochondrial contributions to tissue damage in stroke. Neurochem. Int. (2002) 40(6):511–526.
  • LIPTON S: NO - related species: Neuroprotection verses neurodestruction. In: Primer on Cerebrovascular Diseases (ls' Ed.). K Welch, L Caplan, D Reis, B Siesjo, B Weir (Eds), Academic Press (1997):210–213.
  • BENZ D, CADET P, MANTIONE K, ZHU W, STEFANO G: Tonal nitric oxide and health: anti-bacterial and -viral actions and implications for HIV. Med. Sci. Monk (2002) 8(2):RA27–31.
  • BRUNET LR: Nitric oxide in parasitic infections. Int. Immunopharmacol (2001) 1(8):1457–1467.
  • BLOTTNER D, LUCK G: Just in time and place: NOS/NO system assembly in neuromuscular junction formation. Microsc. Res. Tech. (2001) 55(3):171–180.
  • BREDT DS: Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic. Res. (1999) 31(6):577–596.
  • ••An excellent general review article on thefunctions of NO.
  • SYMEONIDES S, BALK RA: Nitric oxide in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. (1999) 13(2):449x-463x.
  • PANZA JA, GARCIA CE, KILCOYNE CM, QUYYUMI AA, CANNON RO 3rd: Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation (1995) 91(6):1732–1738.
  • STROES ES, KOOMANS HA, DE BRUIN TW, RABELINK TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet (1995) 346(8973):467–471.
  • CASTILLO J, RAMA R, DAVALOS A: Nitric oxide-related brain damage in acute ischemic stroke. Stroke (2000) 31(4):852–857.
  • TARKOWSKI E, RINGQVIST A, ROSENGREN L, JENSEN C, EKHOLM S, WENNMALM A: Intrathecal release of nitric oxide and its relation to final brain damage in patients with stroke. Cerebrovasc. Dis. (2000) 10(3):200–206.
  • HUANG Z, HUANG PL, MA J et al: Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. I Cereb. Blood Flow Metab. (1996) 16:981–987.
  • LI H, FORSTERMANN U: Nitric oxide in the pathogenesis of vascular disease. J. Pathol (2000) 190(3):244–254.
  • HUANG Z, HUANG PL, PANAHIAN N, DALKARA T, FISHMAN MC, MOSKOWITZ MA: Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science (1994) 265:1883–1885.
  • IADECOLA C, ZHANG F, XU S, CASEY R, ROSS ME: Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. Cereb. Blood Flow Metab. (1995) 15(3):378–384.
  • ZHAO X, HAENSEL C, ARAKI E, ROSS ME, IADECOLA C: Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res. (2000) 872(1-2):215–218.
  • SCOTT JF, GRAY CS: Cerebral and systemic pathophysiological responses to acute stroke. Age Ageing (2000) 29(3):197–202.
  • MONCADA S, HIGGS EA: Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. (1995) 9(13):1319–1330.
  • WU G, MEININGER CJ: Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am. Physiol (1995) 269(4, Pt 2):H1312–1318.
  • KAPOSZTA Z, BASKERVILLE PA, MAD GE D, FRASER S, MARTIN JF, MARKUS HS: L-arginine and S-nitrosoglutathione reduce embolization in humans. Circulation (2001) 103(19):2371–2375.
  • BAUDOUIN SV, BATH P, MARTIN JF, DU BOIS R, EVANS TW: L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br. J. Chit. Pharmacol (1993) 36(1):45–49.
  • CREAGER MA, GALLAGHER SJ, GIRERD XJ, COLEMAN SM, DZAU VJ, COOKE JP: L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. (1992) 90(4):1248–1253.
  • CLARKSON P, ADAMS MR, POWE AJ et al.: Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J. Clin. Invest. (1996) 97(8):1989–1994.
  • DREXLER H, ZEIHER AM, MEINZER K, JUST H: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet (1991) 338(8782-8783):1546–1550.
  • CEREMUZYNSKI L, CHAMIEC T, HERBACZYNSKA-CEDRO K: Effect of Suppl.al oral L-arginine on exercise capacity in patients with stable angina pectoris. Am. Cardiol (1997) 80(3):331–333.
  • DUBOIS-RANDE JL, ZELINSKY R, ROUDOT F et al.: Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am. J. Cardiol (1992) 70(15):1269–1275.
  • YAO SK, OBER JC, KRISHNASWAMI A et al.: Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation (1992) 86(4):1302–1309.
  • ADAMS MR, FORSYTH CJ, JESSUP W, ROBINSON J, CELERMAJER DS: Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J. Am. Coll Cardiol (1995) 26(4):1054–1061.
  • BODE-BOGER SM, BOGER RH, CREUTZIG A et al.: L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Chit. Sci. (London) (1994) 87(3):303–310.
  • SAD OSHIMA S, NAGAO T, OKADA Y, FUJII K, IBAYASHI S, FUJISHIMA M: L-arginine ameliorates recirculation and metabolic derangement in brain ischemia in hypertensive rats. Brain Res. (1997) 744(2):246–252.
  • MORIKAWA E, MOSKOWITZ MA, HUANG Z, YOSHIDA T, IRIKURA K, DALKARA T: L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke (1994) 25(2):429–435.
  • MORIKAWA E, HUANG Z, MOSKOWITZ MA: L-arginine decreases infarct size caused by middle cerebral arterial occlusion in SHR. Am. I Physiol. (1992) 263(5, Pt 2):H1632–H1635.
  • IADECOLA C, ZHANG F, XU X: Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am. Physiol (1995) 268(1, Pt 2):R286–R292.
  • ZHANG F, CASEY RM, ROSS ME, IADECOLA C: Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke (1996) 27(2):317–323.
  • IGNARRO LJ, NAPOLI C, LOSCALZO J: Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. (2002) 90(1):21–28.
  • ••A comprehensive article on NO donors.
  • GRYGLEWSKI RJ, MARCINKIEWICZ E, ROBAK J, MICHALSKA Z, MADEJ J: Mesoionic oxatriazoles (MOTA): NO-donating characteristics and pharmacology. Curr. Pharm. Des. (2002) 8(3):167–176.
  • IGNARRO LJ, GRUETTER CA: Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols. Biochim. Biophys. Acta (1980) 631(2):221–231.
  • SINGHAL SS, PIPER JT, SRIVASTAVA SK et al.: Rabbit aorta glutathione S-transferases and their role in bioactivation of trinitroglycerin. Toxicol Appl. Pharmacol (1996) 140(2):378–386.
  • MCGUIRE JJ, ANDERSON DJ, MCDONALD BJ, NARAYANASAMI R, BENNETT BM: Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochem. Pharmacol (1998) 56(7):881–893.
  • RAMOS-ZUNIGA R, VELAZQUEZ-SANTANA H, MERCADO-PIMENTEL R, CERDA-CAMACHO F: Neuroprotection in selective focal ischemia in rats by nitrates, an alternative redox manipulation on nitric oxide: experimental model. Minim. Invasive Neurasurg. (1998) 41(3):152–160.
  • LEONARDI-BEE J, BATH PMW, PHILLIPS SJ, SANDERCOCK PAG: Blood pressure and clinical outcomes in the International Stroke Trial. Stroke (2002) 33:1315–1320.
  • DAHL A, RUSSELL D, NYBERG-HANSEN R, ROOT WELT K: Effect of nitroglycerin on cerebral circulation measured by transcranial doppler and SPECT. Stroke (1989) 20:1733–1736.
  • LISK DR, GROTTA JC, LAMKI LM et al.: Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch. Neurol (1993) 50(8):855–862.
  • HORN J, LIMBURG M: Calcium antagonists for ischemic stroke: a systematic review. Stroke (2001) 32(2):570–576.
  • BATH PMW, PATHANSALI R, IDDENDEN R, BATH FJ: The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. Cerebrovasc. Dis. (2001) 11:265–272.
  • RASHID P, LEONARDI-BEE J, WEAVER C, BATH F, BATH P: The effect of transdermal glyceryl trinitrate on blood pressure and middle cerebral artery volocity in acute stroke. Cerebrovasc. Dis. (2002) 13\(Suppl. 3):53 (Abstract).
  • BATH PMW, WILLMOT M, BATH FJ: Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors in acute ischaemic stroke (Cochrane Review). In: The Cochrane Library (4th Ed.), Oxford, Update Software (2002).
  • BATH PMW, BATH FJ, INVESTIGATORS TE: Efficacy of Nitric Oxide in Stroke (ENOS) trial - a prospective large randomised controlled trial in acute stroke. Cerebrovasc. Dis. (2000) 10\(Suppl. 2):81 (Abstract).
  • IGNARRO LJ, CIRINO G, CASINI A, NAPOLI C: Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol (1999) 34(6):879–886.
  • KOWALUK EA, SETH P, FUNG HL: Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. Pharmacol Exp. Ther. (1992) 262(3):916–922.
  • SALOM JB, ORTI M, CENTENO JM, TORREGROSA G, ALBORCH E: Reduction of infarct size by the NO donors sodium nitroprusside and spermine/NO after transient focal cerebral ischemia in rats. Brain Res. (2000) 865(2):149–156.
  • ZHANG F, IADECOLA C: Nitroprusside improves blood flow and reduces brain damage after focal ischemia. Neuroreport (1993) 4(5):559–562.
  • ZHANG F, WHITE JG, IADECOLA C: Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. Cereb. Blood Flow Metab. (1994) 14:217–226.
  • CHI OZ, WEI HM, WEISS HR: Effects of CAS 754, a new nitric oxide donor, on regional cerebral blood flow in focal cerebral ischemia. Anesthesia Analgesia (1995) 80:703–708.
  • BUTTERWORTH RJ, CLUCKIE A, JACKSON SHD, BUXTON-THOMAS M, BATH PMW: Pathophysiological assessment of nitric oxide (given as sodium nitroprusside) in acute ischaemic stroke. Cerebrovasc. Dis. (1998) 8:158–165.
  • GELB AW, BOISVERT DP, TANG C et al: Primate brain tolerance to temporary focal cerebral ischemia during isoflurane- or sodium nitroprusside-induced hypotension. Anesthesiology (1989) 70(4):678–683.
  • SMITH RP, KRUSZYNA H: Nitroprusside produces cyanide poisoning via reaction with hemoglobin. I Pharmacol Exp. Ther. (1974) 191(3):557–563.
  • NOACK E, FEELISCH M: Molecular aspects underlying the vasodilator action of molsidomine. Cardiovasc. Pharmacol (1989) 14\(Suppl. 11):S1–55.
  • RUDOLPH W, DIRSCHINGER J: Clinical comparison of nitrates and sydnonimines. Eur. Heart J. (1991) 12 (Suppl. E):33–41.
  • GROVES PH, LEWIS MJ, CHEADLE HA, PENNY WJ: SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation (1993) 87(2):590–597.
  • JOHNSON D, FREISCHLAG JA, LESNIAK R et al.: Endothelial damage due to ischemia and reperfusion is prevented with SIN-1. Cardiovasc. Surg. (1998) 6(5):527–532.
  • Multicenter Acute Stroke Trial - Europe (MAST-E). Cerebrovasc. Dis. (1994) 4:241 (Abstract).
  • HOGG N: Biological chemistry and clinical potential of S-nitrosothiols. Free Radic. Biol. Med. (2000) 28(10):1478–1486.
  • DICKS AP, WILLIAMS DL: Generation of nitric oxide from S-nitrosothiols using protein-bound Cu2+ sources. Chem. Biol. (1996) 3(8):655–659.
  • JOURD'HEUIL D, LAROUX FS, MILES AM, WINK DA, GRISHAM MB: Effect of superoxide dismutase on the stability of S-nitrosothiols. Arch. Biochem. Biophys. (1999) 361(2):323–330.
  • GASTON B, SEARS S, WOODS J et al: Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet (1998) 351(9112):1317–1319.
  • RADOMSKI MW REES DD, DUTRA A, MONCADA S: S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br. J. Pharmacol (1992) 107(3):745–749.
  • DE BELDER AJ, MACALLISTER R, RADOMSKI MW MONCADA S, VALLANCE PJ: Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc. Res. (1994) 28(5):691–694.
  • LANGFORD EJ, BROWN AS, WAINWRIGHT RJ et al.: Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet (1994) 344(8935):1458–1460.
  • LANGFORD EJ, WAINWRIGHT RJ, MARTIN JF: Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler. Thromb. Vasc. Biol. (1996) 16(1):51–55.
  • MOLLOY J, MARTIN JF, BASKERVILLE PA, FRASER SC, MARKUS HS: S-nitrosoglutathione reduces the rate of embolization in humans. Circulation (1998) 98(14):1372–1375.
  • KAPOSZTA Z, MARTIN JF, MARKUS HS: Switching off embolization from symptomatic carotid plaque using S-nitrosoglutathione. Circulation (2002) 105(12):1480–1484.
  • EWING JF, YOUNG DV, JANERO DR, GARVEY DS, GRINNELL TA: Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. J. Pharmacol Exp. Ther. (1997) 283(2):947–954.
  • BAUER JA, FUNG HL: Chemical stabilization of a vasoactive S-nitrosothiol with cyclodextrins without loss of pharmacologic activity. Pharm. Res. (1991) 8(10):1329–1334.
  • HOU Y, WANG J, ANDREANA PR et al.: Targeting nitric oxide to cancer cells: cytotoxicity studies of glyco-S-nitrosothiols. Bioorg. Med. Chem. Lett. (1999) 9(15):2255–2258.
  • MEGSON IL, GREIG IR, GRAY GA, WEBB DJ, BUTLER AR: Prolonged effect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat femoral arteries: potential as a slow release nitric oxide donor drug. Br. J. Pharmacol (1997) 122(8):1617H-1624H.
  • SOGO N, CAMPANELLA C, WEBB DJ, MEGSON IL: S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br. J. Pharmacol (2000) 131(6):1236–1244.
  • SOGO N, WILKINSON IB, MACCALLUM H et al: A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clin. Pharmacol Ther. (2000) 68(1):75–81.
  • KHAN F, GREIG IR, NEWTON DJ, BUTLER AR, BELCH JJ: Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet (1997) 350(9075):410–411.
  • MORLEY D, KEEFER LK: Nitric oxide/ nucleophile complexes: a unique class of nitric oxide-based vasodilators. J. Cardio vase. Pharmacol (1993) 22\(Suppl. 7):53–59.
  • PLUTA RIVI, OLDFIELD EH, BOOCK RJ: Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J. Neurosurg. (1997) 87(5):746–751.
  • ZHANG R, ZHANG L, ZHANG Z et al: A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann. Neurol (2001) 50(5):602–611.
  • LOSCALZO J, SMICK D, ANDON N, COOKE J: S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. Pharmacol Exp. Ther. (1989) 249(3):726–729.
  • TAKEUCHI K, YASUHIRO T, ASADA Y, SUGAWA Y: Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion (1998) 59(4)298–307.
  • TASHIMA K, FUJITA A, UMEDA M, TAKEUCHI K: Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Lai. Sci. (2000) 67(13):1639–1652.
  • LECHI C, ANDRIOLI G, GAINO S et al: The antiplatelet effects of a new nitroderivative of acetylsalicylic acid-an IP vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Thromb. Haemost. (1996) 76(5):791–798.
  • LECHI C, GAINO S, TOMMASOLI R et al.: In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. Blood Coagul Fithinolysis (1996) 7(2):206–209.
  • FREDDUZZI S, MARIUCCI G, TANTUCCI M, DEL SOLDATO P, AMBROSINI MV: Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. Neurosci. Lett. (2001) 302(2-3):121–124.
  • NO modified drugs. Nitric Oxide Based Drug Therapy Conference, Porto, Portugal (2002).
  • GOMMA AH, PURCELL HJ, FOX KM: Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil. Drugs (2001) 61(12):1705–1710.
  • KOBAYASHI S, YAMAGUCHI S, OKADA K, SUYAMA N, BOKURA K, MURAO M: Effects of nicorandil on regional cerebral blood flow in patients with chronic cerebral infarction. Preliminary communication. Arzneimittelforschung (1992) 42(9):1086–1089.
  • ANDERSON TJ, MEREDITH IT, YEUNG AC, FREI B, SELWYN AP, GANZ P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl. J. Med. (1995) 332(8):488–493.
  • LAUFS U, LA FATA V, PLUTZKY J, LIAO JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 97(12):1129–1135.
  • AMIN-HANJANI S, STAGLIANO NE, YAMADA M, HUANG PL, LIAO JK, MOSKOWITZ MA: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke (2001) 32(4):980–986.
  • LAUFS U, GERTZ K, HUANG P et al.: Atorvastatin upregulates Type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 31(10):2442–2449.
  • HOBBS AJ, HIGGS A, MONCADA S: Inhibition of nitric oxide synthase as a potential therapeutic target. Ann. Rev Pharmacol Toxicol (1999) 39:191–220.
  • •A good review on the therapeutic potential of NOS inhibitors in many diseases.
  • ALDERTON WK, COOPER CE, KNOWLES RG: Nitric oxide synthases: structure, function and inhibition. Biochem. J. (2001) 357(Pt 3):593–615.
  • ••Excellent article which compares eNOS,INOS and nNOS inhibition profiles in the NOS inhibitors.
  • CARREAU A, DUVAL D, POIGNET H, SCATTON B, VIGE X, NOWICKI JP: Neuroprotective efficacy of N omega-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase. Eur. j Pharmacol (1994) 256(3):241–249.
  • NAGAFUJI T, MATSUI T, KOIDE T, ASANO T: Blockade of nitric oxide formation by N omega-nitro-L-arginine mitigates ischemic brain edema and subsequent cerebral infarction in rats. Neurosci. Lett. (1992) 147(2):159–162.
  • GURSOY-OZDEMIR Y, BOLAY H, SARIBAS O, DALKARA T: Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke (2000) 31(8):1974–1980; discussion 1981.
  • SPINNEWYN B, CORNET S, AUGUET M, CHABRIER PE: Synergistic protective effects of antioxidant and nitric oxide synthase inhibitor in transient focal ischemia. j Cereb. Blood Flow Metab. (1999) 19(2):139–143.
  • TRIFILETTI RR: Neuroprotective effects of NG-nitro-L-arginine in focal stroke in the 7-day old rat. Eur. Pharmacol (1992) 218(1):197–198.
  • SKAPER SD, ANCONA B, FACCI L, FRANCESCHINI D, GIUSTI P: Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway. FASEB J. (1998) 12(9):725–731.
  • ZHANG ZG, REIF D, MACDONALD J et al.: ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats../. Cereb. Blood Flow Metab. (1996) 16(4):599–604.
  • KIDD GA, DOBRUCKI LW, BROVKOVYCH V, BOHR DF, MALINSKI T: Nitric oxide deficiency contributes to large cerebral infarct size. Hypertension (2000) 35(5):1111–1118.
  • BUCHAN AM, GERTLER SZ, HUANG ZG, LI H, CHAUNDY KE, XUE D: Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase. Neuroscience (1994) 61(1):1–11.
  • IZUTA M, CLAVIER N, KIRSCH JR, TRAYSTMAN RJ: Cerebral blood flow during inhibition of brain nitric oxide synthase activity in normal, hypertensive, and stroke-prone rats. Stroke (1995) 26(6):1079–1085.
  • MARGAILL I, ALLIX M, BOULU RG, PLOTKINE M: Dose- and time-dependence of L-NAME neuroprotection in transient focal cerebral ischaemia in rats. Br. J. Pharmaca (1997) 120(1):160–163.
  • ASHWAL S, COLE DJ, OSBORNE TN, PEARCE WJ: Dual effects of L-NAME during transient focal cerebral ischemia in spontaneously hypertensive rats. Am. Physia (1994) 267(1, Pt 2):H276–H284.
  • ASHWAL S, COLE DJ, OSBORNE S, OSBORNE TN, PEARCE WJ: L-NAME reduces infarct volume in a filament model of transient middle cerebral artery occlusion in the rat pup. Pediatr. Res. (1995) 38(5):652–656.
  • IULIANO BA, ANDERSON RE, MEYER FB: Effect of intermittent reperfusion and nitric oxide synthase inhibition on infarct volume during reversible focal cerebral ischemia. Neurosurg. (1995) 83(3):491–495.
  • ASHWAL S, COLE DJ, OSBORNE TN, PEARCE WJ: Low dose L-NAME reduces infarct volume in the rat MCAO/ reperfusion model. .1 Neurosurg. Anesthesia (1993) 5(4):241–249.
  • KULUZ JW, PRADO RJ, DIETRICH WD, SCHLEIEN CL, WATSON BD: The effect of nitric oxide synthase inhibition on infarct volume after reversible focal cerebral ischemia in conscious rats. Stroke (1993) 24(12):2023–2029.
  • STAGLIANO NE, ZHAO W, PRADO R, DEWANJEE MK, GINSBERG MD, DIETRICH WD: The effect of nitric oxide synthase inhibition on acute platelet accumulation and hemodynamic depression in a rat model of thromboembolic stroke. Cereb. Blood Flow Metab. (1997) 17(11):1182–1190.
  • KAMII H, MIKAWA S, MURAKAMI K et al.: Effects of nitric oxide synthase inhibition on brain infarction in SOD-1-transgenic mice following transient focal cerebral ischemia. Cereb. Blood Flow Metab. (1996) 16(6):1153–1157.
  • HAYNES WG, NOON JP, WALKER BR, WEBB DJ: Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J. Hypertens. (1993) 11(12):1375–1380.
  • ALBERT J, SCHEDIN U, LINDQVIST M, MELCHER A, HJEMDAHL P, FROSTELL C: Blockade of endogenous nitric oxide production results in moderate hypertension, reducing sympathetic activity and shortening bleeding time in healthy volunteers. Acta Anaesthesia Land. (1997) 41(9):1104–1113.
  • WHITE RP, DEANE C, VALLANCE P, MARKUS HS: Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke (1998) 29(2):467–472.
  • ESCOTT KJ, BEECH JS, HAGA KK, WILLIAMS SCR, MELDRUM BS, BATH PMW: Cerebroprotective effect of the nitric oxide synthase inhibitors, 1-(2-trifluoromethylphenyl) imidazole (TRIM) and 7-nitro indazole, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. (1998) 18:281–287.
  • GOYAGI T, GOTO S, BHARDWAJ A, DAWSON VL, HURN PD, KIRSCH JR: Neuroprotective effect of sigma(1)-receptor ligand 4-phenyl-I- (4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke (2001) 32(7):1613–1620.
  • YOSHIDA T, LIMMROTH V, IRIKURA K, MOSKOWITZ MA: The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. Cereb. Blood Flow Metab. (1994) 14(6):924–929.
  • KELLY PA, RITCHIE IM, ARBUTHNOTT GW: Inhibition of neuronal nitric oxide synthase by 7- nitroindazole: effects upon local cerebral blood flow and glucose use in the rat. J. Cereb. Blood Flow Metab. (1995) 15(5):766–773.
  • REIF DW, MCCARTHY DJ, CREGAN E, MACDONALD JE: Discovery and development of neuronal nitric oxide synthase inhibitors. Free Radic. Biol. Med. (2000) 28(10):1470–1477.
  • •A good discussion covering the development of some new nNOS inhibitors.
  • CHABRIER PE, AUGUET M, SPINNEWYN B et al: BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc. Natl. Acad. Li. USA (1999) 96(19):10824–10829.
  • O'MAHONY D, KENDALL M: Nitric oxide in acute ischaemic stroke: a target for neuroprotection. Neura Neurosurg. Psychiatry (1999) 67:1–3.
  • •Excellent short review article on the therapeutic potential of NO therapeutics in stroke, with a particular emphasis on the iNOS inhibitors.
  • NELSON RJ, DEMAS GE, HUANG PL et al.: Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature (1995) 378(6555):383–386.
  • IVANOVA S, BOTCHKINA GI, AL-ABED Y et Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. Exp. Med. (1998) 188(2):327–340.
  • COCKROFT KM, MEISTRELL M 3rd, ZIMMERMAN GA et al.: Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke (1996) 27(8):1393–1398.
  • NAGAYAMA M, ZHANG F, IADECOLA C: Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. J. Cereb. Blood Flow Metab. (1998) 18(10):1107–1113.
  • CASH D, BEECH JS, RAYNE RC, BATH PMW, MELDRUM BS, WILLIAMS SCR: Neuroprotective effect of aminoguanidine on transient focal ischaemia in the rat brain. Brain Res. (2001) 905:91–103.
  • BUCALA R, VLASSARA H: Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. (1995) 26(6):875–888.
  • GARVEY EP, OPLINGER JA, FURFINE ES et al: 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. j. Biol. Chem. (1997) 272(8):4959–4963.
  • PARMENTIER S, BOHME GA, LEROUET D et al.: Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. BE I Pharmacol. (1999) 127(2):546–552.
  • GANDOLFO C, SANDERCOCK P, CONTI M: Lubeluzole for acute ischaemic stroke. Cochrane Database Syst. Rev (2002) 1:CD001924.
  • FLOYD RA, HENSLEY K: Nitrone inhibition of age-associated oxidative damage. Ann. NY Acad. Li. (2000) 899:222–237.
  • 9th European Stroke Conference. Vienna, Austria, May 24–27, 2000. Cerebrovasc. Dis. (2000) 10\(Suppl. 2):1H116 (Abstract).
  • MASON RB, PLUTA RIVI, WALBRIDGE S, WINK DA, OLDFIELD EH, BOOCK RJ: Production of reactive oxygen species after reperfusion in vitro and in vivo: protective effect of nitric oxide. J. Neurosurg. (2000) 93(1):99–107.
  • BEDNAR MM, GROSS CE, HOWARD DB, RUSSELL SR, THOMAS GR: Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model of thromboembolic stroke. Exp. Neurol. (1997) 146(2):513–517.
  • ALEXANDER MY, BROSNAN MJ, HAMILTON CA et al.: Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model. Cardiovasc. Res. (1999) 43(3):798–807.
  • STROKE THERAPY ACADEMIC INDUSTRY ROUNDTABLE (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 30:2752–2758.
  • STROKE THERAPY ACADEMIC INDUSTRY ROUNDTABLE II (STAIR-II): Recommendations for clinical trial evaluation of acute stroke therapies. Stroke (2001) 32:1598–1606.
  • COERT BA, ANDERSON RE, MEYER FB: A comparative study of the effects of two nitric oxide synthase inhibitors and two nitric oxide donors on temporary focal cerebral ischemia in the Wistar rat. J. Neurosurg. (1999) 90(2):332–338.
  • KIRIS T, KARASU A, YAVUZ C et al: Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. Acta Neurochir. (Wien) (1999) 141(12):1323–1328; discussion 1328–1329.

Websites

  • http://www.nottingham.ac.uldstroke-medicine/enosindex.htm Efficacy of Nitric Oxide (ENOS) trial.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.